LAB News and Press, Standard BioTools Inc.

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenu...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

Standard BioTools Inc. (LAB) is expected to report $-0.05 for Q4 2025

2026-02-23 17:38:54 ET Standard BioTools Inc. (LAB) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 7.69%. The average open to low on the day of earnings was -7.33%. The average open to ...

2026-02-23 17:33:55 ET Standard BioTools Inc. (LAB) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in LAB stock price following earnings has averaged ±4.79% , with a median of 2.65%. ...

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq:...

2026-01-30 09:34:08 ET More on Illumina Illumina: What Is Next In This Sequence? Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript ...

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy  ...

2026-01-08 07:40:16 ET Standard BioTools ( LAB ) announced preliminary revenue results for the fourth quarter and full year 2025, expects Q4 revenue of about $56 million, with $24 million from continuing operations vs. consensus of $18.50M.... Read the full article...

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 comb...